Pages that link to "Q74633475"

The following pages link to Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity (Q74633475):

Displaying 25 items.

• Apolipoprotein C-III: understanding an emerging cardiovascular risk factor (Q24318657) (← links)
• Metabolic complications of obesity. Pathophysiologic considerations (Q33904956) (← links)
• Pharmacologic inhibition of sphingomyelin synthase (SMS) activity reduces apolipoprotein-B secretion from hepatocytes and attenuates endotoxin-mediated macrophage inflammation (Q33916433) (← links)
• Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation (Q35113488) (← links)
• Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies (Q35754362) (← links)
• Plasma kinetics of an LDL-like nanoemulsion and lipid transfer to HDL in subjects with glucose intolerance. (Q35865006) (← links)
• Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. (Q35913725) (← links)
• Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice (Q36132481) (← links)
• Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma. (Q36263057) (← links)
• Effect of weight loss, independent of change in diet composition, on apolipoprotein AI kinetic in men with metabolic syndrome. (Q36462080) (← links)
• Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies (Q36487064) (← links)
• Central nervous system neuropeptide Y signaling via the Y1 receptor partially dissociates feeding behavior from lipoprotein metabolism in lean rats (Q36494405) (← links)
• Fatty liver, insulin resistance, and dyslipidemia (Q37119305) (← links)
• Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. (Q37671062) (← links)
• The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism (Q38035073) (← links)
• Fat compartments and apolipoprotein B-100 kinetics in overweight-obese men. (Q44279291) (← links)
• Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. (Q44400061) (← links)
• Grape seed proanthocyanidins correct dyslipidemia associated with a high-fat diet in rats and repress genes controlling lipogenesis and VLDL assembling in liver. (Q45937715) (← links)
• Plasma triglycerides after oral glucose load specifically associate with metabolic risk markers in healthy type 2 diabetes offspring (Q51375201) (← links)
• Non-Cholesterol Sterol Concentrations as Biomarkers for Cholesterol Absorption and Synthesis in Different Metabolic Disorders: A Systematic Review (Q61799895) (← links)
• Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency (Q64379711) (← links)
• Relationship between altered postprandial lipemia and insulin resistance in normolipidemic and normoglucose tolerant obese patients (Q73775756) (← links)
• Lipid disorders in obesity (Q74298998) (← links)
• Relationships in women between body mass index and the intravascular metabolism of chylomicron-like emulsions (Q80866810) (← links)
• Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes (Q83263359) (← links)